Genmab A/S Stock

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 10:59:40 2024-04-24 am EDT 5-day change 1st Jan Change
1,972 DKK -1.79% Intraday chart for Genmab A/S -1.74% -8.49%
Sales 2024 * 19.66B 2.82B Sales 2025 * 23.51B 3.37B Capitalization 128B 18.36B
Net income 2024 * 5.11B 733M Net income 2025 * 6.76B 970M EV / Sales 2024 * 5.11 x
Net cash position 2024 * 27.45B 3.94B Net cash position 2025 * 34.52B 4.95B EV / Sales 2025 * 3.97 x
P/E ratio 2024 *
25.3 x
P/E ratio 2025 *
19.4 x
Employees 2,204
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.87%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Genmab A/S

1 day-1.79%
1 week-1.74%
Current month-5.37%
1 month-5.28%
3 months+4.53%
6 months-4.27%
Current year-8.49%
More quotes
1 week
1 960.50
Extreme 1960.5
2 054.00
1 month
1 960.50
Extreme 1960.5
2 137.00
Current year
1 825.00
Extreme 1825
2 227.00
1 year
1 825.00
Extreme 1825
2 939.00
3 years
1 825.00
Extreme 1825
3 327.00
5 years
1 075.50
Extreme 1075.5
3 327.00
10 years
180.10
Extreme 180.1
3 327.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 98-12-31
Director of Finance/CFO 46 06-12-31
Chief Operating Officer 53 20-03-22
Members of the board TitleAgeSince
Chairman 63 16-12-31
Director/Board Member 73 03-10-31
Director/Board Member 63 15-12-31
More insiders
Date Price Change Volume
24-04-24 1,972 -1.79% 150,555
24-04-23 2,008 -1.08% 131,041
24-04-22 2,030 +1.20% 108,395
24-04-19 2,006 +0.58% 94,388
24-04-18 1,994 -0.62% 94,295

Delayed Quote Nasdaq Copenhagen, April 24, 2024 at 10:59 am EDT

More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
1,972 DKK
Average target price
2,422 DKK
Spread / Average Target
+22.81%
Consensus